

# RAUCON *BD Executive News*

Vol. 16 # 14 | 30 July 2020

## Hot Company News

\* Partnership: **Adalvo** has entered into partnership with **AmbioPharm**, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialisation of several complex pharmaceutical products in key global markets. The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology. 29 Jul 2020 (www.adalvo.com)

\* Acquisition: **AGC Biologics** will complete the announced acquisition of Italian biotech **Molecular Medicine SpA** on 31 July in a deal worth up to EUR 240 million. 28 Jul 2020 (www.agcbio.com)

\* Investment: **Amgen** announced an additional investment of \$421 million in **BeiGene's** registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at 20.3%. This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China. 12 Jul 2020 (www.amgen.com)

\* Acquisition: **BetterLife Pharma Inc.**, an emerging biotechnology company with proprietary interferon-based therapeutic technologies, is pleased to provide an update on the results of the Special Meeting of the shareholders of **Altum Pharmaceuticals Inc.** to approve the merger with BetterLife. 30 Jul 2020 (abetterlifepharma.com)

\* Acquisition: **Creo Medical Group** acquired **Albyn Medical**, a Spanish manufacturer of gastroenterology, urology and endoscopy products, for an equity value of €24.8m. 24 Jul 2020 (creomedical.com)

\* Acquisition: **Cure Pharmaceutical** has entered into a Memorandum

of Understanding to acquire 100% of privately held **Sera Labs** for total up-front consideration of \$20 million. 28 Jul 2020 (www.curepharmaceutical.com)

\* Resurgence: Bankrupt **Eastman Kodak** resurges with the help of a \$765 million loan from the U.S. International Development Finance Corporation (DFC) and the U.S. Department of Defense and will now „produce critical pharmaceutical components that have been identified as essential but have lapsed into chronic national shortage“ under the Defense Production Act. DFC's loan - facilitated by President Trump's May 14 Executive Order 13922 „to leverage its financial tools to re-shore production of strategic resources and strengthen related domestic supply chains“, will accelerate Kodak's time to market by supporting startup costs needed to repurpose and expand the company's existing facilities by incorporating continuous manufacturing and advanced technology capabilities. 28 Jul 2020 (www.kodak.com)

\* Acquisition: **Gilead Sciences, Inc.** will invest \$300 million to acquire a 49.9 percent equity interest in **Tizona Therapeutics, Inc.**, a privately held company developing first-in-class cancer immunotherapies. 21 Jul 2020 (www.gilead.com)

\* Acquisition: **La Jolla Pharmaceutical Company** acquired **Tetraphase Pharmaceuticals, Inc.** for \$43.0 million in upfront cash plus potential future cash payments of up to \$16.0 million pursuant to contingent value rights. Tetraphase is a biopharmaceutical company focused on commercialising its novel tetracycline XERAVA™ (eravacycline) to treat serious and life-threatening infections. 28 Jul 2020 (www.ljpc.com)

\* Acquisition: **LGM Pharma** has acquired the formulation development and drug product contract manufacturing business of **Nexgen**

**Pharma, Inc.** Financial details of were not disclosed. 27 Jul 2020 (www.lgmpharma.com)

\* Distribution: **Nabriva Therapeutics** has entered into an exclusive agreement with subsidiaries of **Merck & Co. Inc.**, Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and paediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms 15 Jul 2020 (www.nabriva.com)

Expansion: **PCI Pharma Services** created a new Clinical Center of Excellence in Western Europe at its Berlin location, a major investment that will be part of PCI's global strategy to expand its clinical supply-chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021. 30 Jul 2020

\* Acquisition: One of the wholly-owned subsidiaries of **Taro Pharmaceutical Industries**, a subsidiary of **Sun Pharma Industries** has agreed to acquire by way of purchase of all outstanding shares of **Aquinox Pharmaceuticals (Canada) Inc.**, a corporation organised and existing under the laws of the Province of British Columbia that carries on the business of research and development of pharma products for purposes of their commercialisation. The cost of acquisition is about \$8.2 million. 29 Jul 2020 (www.sunpharma.com)

## BD People on the Move

\* Autobahn Therapeutics: **Scott Forrest**, Ph.D., joining from Inception Therapeutics, where

he served as chief operating officer and chief financial officer, has been hired as chief business officer, overseeing corporate development, portfolio strategic planning and financial strategy. (Press Release 15 Jul 2020)

\* Chemo Group: **Dennis Kuck**, who has been Senior Commercial Manager will be leaving the company at the end of this week in order to accept a new challenge in the pharmaceutical industry. (Pers Comm 27 Jul 2020)

\* Kiadis Pharma BV: **Ray Barlow**, Ph.D., most recently as chief executive officer at e-therapeutics PLC, has been appointed as chief business officer, responsible for all corporate business development initiatives, including out-licensing, pharma and biotech partnerships, development and commercialization collaborations, and potential mergers and acquisitions. (Press Release 13 Jul 2020)

\* Krystal Biotech, Inc.: **Whitney Ijlem**, previously with Guggenheim Securities, has been appointed to the newly created position of Senior Vice President, Strategy and Business Development. (Press Release 20 Jul 2020)

\* MedX Health Corp.: **Nick Hoffman** has been appointed as Director Business Development. (Press Release 29 Jul 2020)

\* MIDAS Pharma GmbH: **Roman Hirsch**, who has been Vice President EU & US Licensing, has left the company in order to pursue a new challenge within the pharmaceutical industry (Pers Comm 14 Jul 2020)

\* Taiho Oncology, Inc.: **Stephen Yoder**, MD, MBA, most recently head of Bristol Myers Squibb's Hematology and Cell Therapy Search & Evaluation team in Business Development. has been appointed as Vice President, Business Development, effective June 15, 2020. (Press Release 15 Jul 2020)